Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00017082 · ClinicalTrials.gov registry record · Phase 2

Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

A Phase 2 study of Colorectal Cancer, sponsored by Prologue Research International.

Completed
Registry status
Phase 2
Development phase
10
Study locations

NCT00017082: Completed Phase 2 study of Colorectal Cancer, sponsored by Prologue Research International.

NCT00017082 is a Phase 2 study of Colorectal Cancer that has completed, run by Prologue Research International. The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00017082, a Phase 2 study of Colorectal Cancer, has completed, sponsored by Prologue Research International.

COMPLETED
Registry status
Phase 2
Development phase
10
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent metastatic colorectal cancer.

Conditions Studied

Interventions

  • DRUG oxaliplatin

Study Locations (10)

North Carolina

  • Southeastern Medical Oncology Center - Goldsboro
  • Raleigh Hematology/Oncology Associates - Wake Practice - Raleigh

Pennsylvania

  • Pinnacle Health Hospitals - Harrisburg
  • University of Pennsylvania Cancer Center - Philadelphia

District of Columbia

  • Washington Cancer Institute - Washington D.C.

Florida

  • Comprehensive Cancer Care Specialists of Boca Raton - Boca Raton

Kentucky

  • Kentuckiana Cancer Institute - Louisville

Nebraska

  • University of Nebraska Medical Center - Omaha

New York

  • Veterans Affairs Medical Center - Albany - Albany

Tennessee

  • Memphis Cancer Center - Memphis

Trial Details

FieldValue
Start Date 2001-04
Est. Completion 2010-12
Phase Phase 2

Sponsor

Prologue Research International

3 total trials

What the Registry Record Tells You About NCT00017082

The ClinicalTrials.gov registry entry for NCT00017082 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Prologue Research International, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which oxaliplatin is the first listed.

NCT00017082 reports 10 study locations spanning 8 distinct geographic areas - top geographies include North Carolina, Pennsylvania, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00017082 about?

NCT00017082 is a clinical study titled "Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent metastatic colorectal cancer.

What is the current status of trial NCT00017082?

This trial is currently completed. It is a Phase 2 study. The study started on 2001-04. Estimated completion is 2010-12.

What conditions does trial NCT00017082 study?

This clinical trial studies the following conditions: Colorectal Cancer.

What interventions are being tested in trial NCT00017082?

The interventions under investigation include: oxaliplatin (DRUG).

Who is sponsoring clinical trial NCT00017082?

This trial is sponsored by Prologue Research International, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00017082 being conducted?

This trial has 10 study locations across District of Columbia, Florida, Kentucky, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.